替吉奥（S-1）交替给药同步放化疗治疗老年头颈部肿瘤患者的可行性。
Feasibility of concurrent chemoradiotherapy with S-1 administered on alternate days for elderly patients with head and neck cancer.
机构信息
Department of Otolaryngology, Head and Neck Surgery, Kyorin University School of Medicine, Tokyo, Japan.
出版信息
Anticancer Res. 2012 Sep;32(9):4035-40.
BACKGROUND
Concurrent chemoradiotherapy (CCRT) improves survival and organ preservation in patients with head and neck squamous cell carcinoma (HNSCC), compared with radiotherapy. However, such regimens are not always feasible because of substantial toxicities. Therefore, we evaluated the feasibility of S-1, administered on alternate days, and concurrent radiotherapy among elderly patients with HNSCC.
PATIENTS AND METHODS
Nineteen eligible patients were treated with CCRT. S-1 was administered at a dose of 80 mg/day on alternate days with the intention to reduce the toxicity.
RESULTS
With a median follow-up period of 19.2 months, the two-year overall survival rates were 62.5% for patients with stage III disease and 50.0% for those with stage IV. The Complete Response (CR) rates were 100% for stage II and 66.7% for stage III/IV disease. Grade 3 mucositis occurred in three patients. Grade 3 or 4 hematological toxicities were not observed.
CONCLUSION
CCRT with S-1 administered on alternate days was effective and well-tolerated among elderly patients with HNSCC.
背景
与单纯放疗相比，头颈部鳞状细胞癌（HNSCC）患者同步放化疗（CCRT）可提高生存率和器官保存率。然而，由于毒性较大，并非所有患者都适用此类方案。因此，我们评估了 S-1 隔日给药联合放疗在老年 HNSCC 患者中的可行性。
患者和方法
19 例符合条件的患者接受了 CCRT 治疗。S-1 以 80mg/天的剂量隔日给药，旨在减轻毒性。
结果
中位随访 19.2 个月，Ⅲ期患者的 2 年总生存率为 62.5%，Ⅳ期患者为 50.0%。Ⅱ期患者的完全缓解（CR）率为 100%，Ⅲ/Ⅳ期患者为 66.7%。3 例患者发生 3 级黏膜炎。未观察到 3 级或 4 级血液学毒性。
结论
S-1 隔日给药联合 CCRT 治疗老年 HNSCC 患者有效且耐受性良好。
Zotero 插件